If a patient is on Advair (fluticasone propionate 250 µg / salmeterol 50 µg) and remains uncontrolled, what starting dose of Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) should be used?

Switching from Advair to Trelegy Ellipta for Uncontrolled Asthma

Start Trelegy Ellipta 100/62.5/25 mcg once daily when switching from Advair 250/50 mcg, as this is the FDA-recommended starting dose for asthma patients on moderate-dose ICS/LABA therapy.

FDA-Approved Dosing Strategy

The FDA label for Trelegy Ellipta provides clear guidance for asthma patients transitioning from other therapies 1:

• Starting dose options: Either Trelegy 100/62.5/25 mcg OR 200/62.5/25 mcg once daily
• Dose selection factors: Consider disease severity, previous ICS dosage, current symptom control, and future exacerbation risk 1
• For inadequate response: If Trelegy 100/62.5/25 mcg doesn't provide adequate control, escalate to 200/62.5/25 mcg 1

Recommended Approach for Advair 250/50 Patients

Begin with Trelegy 100/62.5/25 mcg once daily for most patients switching from Advair 250/50 mcg 1. This conservative approach is justified because:

• Fluticasone furoate (in Trelegy) is approximately twice as potent as fluticasone propionate (in Advair) on a microgram-per-microgram basis
• The addition of umeclidinium (LAMA) provides a third mechanism of action not present in Advair 1
• You can safely escalate to Trelegy 200/62.5/25 mcg if the lower dose proves insufficient after an adequate trial 1

Critical Pre-Switch Assessment

Before escalating therapy, GINA guidelines emphasize evaluating reversible factors 2:

• Inhaler technique: Incorrect technique is a common cause of apparent treatment failure
• Medication adherence: Poor adherence mimics inadequate dosing
• Comorbid conditions: Rhinosinusitis, GERD, obesity, or vocal cord dysfunction may cause persistent symptoms
• Environmental triggers: Ongoing allergen or irritant exposure
• Type-2 inflammation biomarkers: Consider eosinophil count or FeNO to guide therapy intensity 2

When to Consider Starting at Trelegy 200/62.5/25 mcg

Start directly with the higher dose (200/62.5/25 mcg) if the patient has 1:

• Severe uncontrolled asthma with frequent exacerbations (≥2 per year requiring systemic corticosteroids)
• Recent hospitalization or emergency department visit for asthma
• Significantly impaired lung function (FEV1 <60% predicted)
• High symptom burden despite confirmed good adherence and technique with Advair

Evidence for Triple Therapy Effectiveness

Real-world data demonstrates significant benefits of triple therapy in symptomatic patients 3:

• Forced expiratory volume in 1 second (FEV1) significantly improved with FF/UMEC/VI 200/62.5/25 mcg (p<0.001)
• Peak flow increased significantly (p<0.001)
• Asthma Control Test scores improved (p<0.01)
• Peripheral airway dilation was demonstrated on pulmonary function testing 3

Safety Considerations

Important caveats when initiating triple therapy 1:

• LABAs must never be used as monotherapy for asthma due to increased mortality risk 4, 1
• Instruct patients to rinse mouth after inhalation to reduce oropharyngeal candidiasis risk 1
• Triple therapy is NOT for acute bronchospasm relief—patients need a separate rescue inhaler 1
• Maximum dose is Trelegy 200/62.5/25 mcg once daily; do not exceed this 1

Monitoring and Escalation Timeline

After initiating Trelegy 100/62.5/25 mcg 1:

• Reassess at 4-12 weeks for symptom control and lung function
• If inadequate response, escalate to 200/62.5/25 mcg
• If still inadequate on maximum dose, re-evaluate diagnosis and consider biologics or other therapeutic options 1